

CPT Code	Long Descriptor
86318	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single-step method (eg, reagent strip);
86328	Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single-step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])
86408	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen
86409	Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer
86413	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative
86769	Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])
87301	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; adenovirus enteric types 40/41
87305	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; Aspergillus
87320	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; Chlamydia trachomatis
87324	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; Clostridium difficile toxin(s)
87327	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; Cryptococcus neoformans
87328	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; cryptosporidium
87329	Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; giardia

- 87332 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; cytomegalovirus
- 87335 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; *Escherichia coli* 0157
- 87336 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; *Entamoeba histolytica* dispar group
- 87337 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; *Entamoeba histolytica* group
- 87338 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; *Helicobacter pylori*, stool
- 87339 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; *Helicobacter pylori*
- 87340 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; hepatitis B surface antigen (HBsAg)
- 87341 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; hepatitis B surface antigen (HBsAg) neutralization
- 87350 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; hepatitis Be antigen (HBeAg)
- 87380 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; hepatitis, delta agent
- 87385 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; *Histoplasma capsulatum*

- 87389 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result
- 87390 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; HIV-1
- 87391 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; HIV-2
- 87400 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; Influenza, A or B, each
- 87420 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; respiratory syncytial virus
- 87425 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; rotavirus
- 87426 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19])
- 87427 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; Shiga-like toxin
- 87428 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B
- 87430 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; Streptococcus, group A
- 87449 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; not otherwise specified, each organism

- 87451 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; polyvalent for multiple organisms, each polyvalent antiserum
- 87635 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique
- 87636 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique
- 87637 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique
- 87802 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group B
- 87803 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Clostridium difficile toxin A
- 87806 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies
- 87804 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Influenza
- 87807 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; respiratory syncytial virus
- 87811 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])
- 87808 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Trichomonas vaginalis
- 87809 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; adenovirus
- 87810 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Chlamydia trachomatis
- 87850 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Neisseria gonorrhoeae
- 87880 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; Streptococcus, group A
- 87899 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; not otherwise specified
- 0202U Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected
- 0223U Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected

- 0224U Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed
Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome
- 0225U coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected
- 0226U Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum
Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3
- 0240U targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected
- 0241U Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected
- 99072 Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency, as defined by law, due to respiratory-transmitted infectious disease

0001A

Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose

0002A

Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose

0011A

Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose

0012A

Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose

91300

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use

91301

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use

RELATED CPT CODES

Medium Descriptor	Short Descriptor	Published Date (To AMA Website)	Effective Date	Type of Change
IA INFECTIOUS AGT ANTIBODY QUAL/SEMIQ 1STEP METH	IA INFECTIOUS AGENT ANTIBODY	10-Apr-20	10-Apr-20	REVISED
IA INFECTIOUS AGT ANTIBODY SARS- COV-2 COVID-19	IA NFCT AB SARSCOV2 COVID19	10-Apr-20	10-Apr-20	NEW
NEUTRALIZING ANTIBODY SARS-COV- 2 SCREEN	NEUTRLZG ANTB SARSCOV2 SCR	10-Aug-20	10-Aug-20	NEW
NEUTRALIZING ANTIBODY SARS-COV- 2 TITER	NEUTRLZG ANTB SARSCOV2 TITER	10-Aug-20	10-Aug-20	NEW
SEV AQT RESPIR SYND	SARS-COV-2 ANTB			
CORONAVIRUS 2 ANTIBODY QUAN	QUANTITATIVE	8-Sep-20	8-Sep-20	NEW
ANTB SEVERE AQT RESPIR SYND	SARS-COV-2 COVID-19			
SARS-COV-2 COVID-19	ANTIBODY	10-Apr-20	10-Apr-20	NEW
IAAD IA ADENOVIRUS ENTERIC TYP 40/41	ADENOVIRUS AG IA	6-Oct-20	6-Oct-20	REVISED
IAAD IA ASPERGILLUS	ASPERGILLUS AG IA	6-Oct-20	6-Oct-20	REVISED
IAAD IA CHLAMYDIA TRACHOMATIS	CHYLMD TRACH AG IA	6-Oct-20	6-Oct-20	REVISED
IAAD IA CLOSTRIDIUM DIFFICILE TOXIN	CLOSTRIDIUM AG IA	6-Oct-20	6-Oct-20	REVISED
IAAD IA CRYPTOCOCCUS NEOFORMANS	CRYPTOCOCCUS NEOFORM AG IA	6-Oct-20	6-Oct-20	REVISED
IAAD IA CRYPTOSPORIDIUM	CRYPTOSPORIDIUM AG IA	6-Oct-20	6-Oct-20	REVISED
IAAD IA GIARDIA	GIARDIA AG IA	6-Oct-20	6-Oct-20	REVISED

IAAD IA CYTOMEGALOVIRUS	CYTOMEGALOVIRUS AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA ESCHERICHIA COLI 0157	E COLI 0157 AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA ENTAMOEBA HISTOLYTICA DISPAR GRP	ENTAMOEBA HIST DISPR AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA ENTAMOEBA HISTOLYTICA GRP	ENTAMOEBA HIST GROUP AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA HPYLORI STOOL	HPYLORI STOOL AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA HPYLORI	H PYLORI AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA HEPATITIS B SURFACE ANTIGEN	HEPATITIS B SURFACE AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA HEPATITIS B SURFACE AG NEUTRALIZATION	HEPATITIS B SURFACE AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA HEPATITIS BE ANTIGEN	HEPATITIS BE AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA HEPATITIS DELTA ANTIGEN	HEPATITIS DELTA AGENT AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA HISTOPLASMA CAPSULATUM	HISTOPLASMA CAPSUL AG IA	6-Oct-20	6-Oct-20 REVISED

IAAD IA HIV-1 AG W/HIV-1 & HIV-2 ANTBDY SINGLE	HIV-1 AG W/HIV-1 AB AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA HIV-1	HIV-1 AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA HIV-2	HIV-2 AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA INFLUENZA A/B EACH	INFLUENZA A/B EACH AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA RESPIRATORY SYNCYTIAL VIRUS	RESP SYNCYTIAL VIRUS AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA ROTAVIRUS	ROTAVIRUS AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA SEVERE AQT RESPIR SYND CORONAVIRUS	SARSCOV CORONAVIRUS AG IA	25-Jun-20	25-Jun-20 REVISED
IAAD IA SHIGA-LIKE TOXIN	SHIGA-LIKE TOXIN AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA SARSCOV & INFLUENZA VIRUS TYPES A&B	SARSCOV & INF VIR A&B AG IA	10-Nov-20	10-Nov-20 NEW
IAAD IA STREPTOCOCCUS GROUP A	STREP A AG IA	6-Oct-20	6-Oct-20 REVISED
IAAD IA NOT OTHERWISE SPECIFIED EACH ORGANISM	NOS EACH ORGANISM AG IA	6-Oct-20	6-Oct-20 REVISED

IAAD IA POLYV MLT ORGANISMS EA POLYV ANTISERUM	POLYVALENT MULT ORG EA AG IA	6-Oct-20	6-Oct-20 REVISED
IADNA SARS-COV-2 COVID-19 AMPLIFIED PROBE TQ	SARS-COV-2 COVID-19 AMP PRB	13-Mar-20	13-Mar-20 NEW
IADNA SARSCOV2& INF A&B MULT AMPLIFIED PROBE TQ	SARSCOV2 & INF A&B AMP PRB	6-Oct-20	6-Oct-20 NEW
IADNA SARSCOV2 & INF A&B & RSV MULT AMP PROBE TQ	SARSCOV2&INF A&B&RSV AMP PRB	6-Oct-20	6-Oct-20 NEW
IAADIADOO STREPTOCOCCUS GROUP B	STREP B ASSAY W/OPTIC	6-Oct-20	6-Oct-20 REVISED
IAADIADOO CLOSTRIDIUM DIFFICILE TOXIN A	CLOSTRIDIUM TOXIN A W/OPTIC	6-Oct-20	6-Oct-20 REVISED
IAADIADOO HIV1 ANTIGEN W/HIV1 & HIV2 ANTIBODIES	HIV AG W/HIV1&2 ANTB W/OPTIC	6-Oct-20	6-Oct-20 REVISED
IAADIADOO INFLUENZA	INFLUENZA ASSAY W/OPTIC	6-Oct-20	6-Oct-20 REVISED
IAADIADOO RESPIRATORY SYNCTIAL VIRUS	RSV ASSAY W/OPTIC	6-Oct-20	6-Oct-20 REVISED
IAADIADOO SEVERE AQT RESPIR SYND CORONAVIRUS	SARS-COV-2 COVID19 W/OPTIC	6-Oct-20	6-Oct-20 NEW
IAADIADOO TRICHOMONAS VAGINALIS	TRICHOMONAS ASSAY W/OPTIC	6-Oct-20	6-Oct-20 REVISED
IAADIADOO ADENOVIRUS	ADENOVIRUS ASSAY W/OPTIC	6-Oct-20	6-Oct-20 REVISED
IAADIADOO CHLAMYDIA TRACHOMATIS	CHYLMD TRACH ASSAY W/OPTIC	6-Oct-20	6-Oct-20 REVISED
IAADIADOO NEISSERIA GONORRHOEAE	N. GONORRHOEAE ASSAY W/OPTIC	6-Oct-20	6-Oct-20 REVISED
IAADIADOO STREPTOCOCCUS GROUP A	STREP A ASSAY W/OPTIC	6-Oct-20	6-Oct-20 REVISED
IAADIADOO NOT OTHERWISE SPECIFIED	AGENT NOS ASSAY W/OPTIC	6-Oct-20	6-Oct-20 REVISED
NFCT DS BCT/VIR RESPIR DNA/RNA 22 TRGT SARSCOV2	NFCT DS 22 TRGT SARS-COV-2	20-May-20	20-May-20 NEW
NFCT DS BCT/VIR RESPIR DNA/RNA 22 TRGT SARSCOV2	NFCT DS 22 TRGT SARS-COV-2	25-Jun-20	25-Jun-20 NEW

ANTB SEV AQT RESPIR SYND CORONAVIRUS 2 TITER(S)	ANTIBODY SARS-COV- 2 TITER(S)	25-Jun-20	25-Jun-20 NEW
NFCT DS DNA&RNA 21 TARGETS SARS-COV-2 AMP PROBE	NFCT DS DNA&RNA 21 SARSCOV2	10-Aug-20	10-Aug-20 NEW
SUROGAT VIR NEUTRLZJ TST SARSCOV2 ELISA PLSM SRM	SVNT SARSCOV2 ELISA PLSM SRM	10-Aug-20	10-Aug-20 NEW
NFCT DS RNA 3 TARGETS UPPER RESPIRATORY SPECIMEN	NFCT DS VIR RESP RNA 3 TRGT	6-Oct-20	6-Oct-20 NEW
NFCT DS RNA 4 TARGETS UPPER RESPIRATORY SPECIMEN	NFCT DS VIR RESP RNA 4 TRGT	6-Oct-20	6-Oct-20 NEW
ADDL SUPL MATRL&STAF TM DRG PHE RES-TR NFCT DS	ADDL SUPL MATRL&STAF TM PHE	8-Sep-20	8-Sep-20 NEW Effective upon receiving Emergency Use Authorizati on or approval from the Food and Drug Administra
IMM ADMN SARSCOV2 30MCG/0.3ML DIL RECON 1ST DOSE	ADM SARSCOV2 30MCG/0.3ML 1ST	10-Nov-20	tion NEW

IMM ADMN SARSCOV2
30MCG/0.3ML DIL RECON 2ND
DOSE

ADM SARSCOV2
30MCG/0.3ML 2ND

10-Nov-20

Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration

NEW

IMM ADMN SARSCOV2 100
MCG/0.5 ML 1ST DOSE

ADM SARSCOV2
100MCG/0.5ML1ST

10-Nov-20

Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration

NEW

IMM ADMN SARSCOV2 100
MCG/0.5 ML 2ND DOSE

ADM SARSCOV2
100MCG/0.5ML2ND

10-Nov-20

Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration

NEW

SARSCOV2 VACCINE DIL RECON 30
MCG/0.3 ML IM USE

SARSCOV2 VAC
30MCG/0.3ML IM

10-Nov-20

Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration

NEW

SARSCOV2 VACCINE 100 MCG/0.5
ML IM USE

SARSCOV2 VAC
100MCG/0.5ML IM

10-Nov-20

Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration

NEW